#USA #Spatial Biology #Sirona Dx #Parhelia Biosciences #Ashland, Oregon

Parhelia and Sirona Dx: A Strategic Partnership in Spatial Biology

In a groundbreaking announcement, Parhelia Biosciences and Sirona Dx have formed a strategic alliance focused on revolutionizing the field of spatial biology. This partnership aims to enhance adoption in various domains including translational research, clinical trials, and precision medicine initiatives. The global landscape of biology is witnessing a shift as the two companies seek to streamline existing workflows, making them not only more efficient but also scalable and reproducible.

The Challenges in Spatial Biology

Despite the advancements in spatial biology technologies that improve our understanding of tissue architecture and cellular interactions, several hurdles persist. Many of the current workflows are manual, have high costs, and aren't easily scalable. Such limitations hinder reproducibility across different labs and pose significant barriers to broader clinical applications.

To address these issues, Parhelia and Sirona Dx bring together their respective strengths to solve these critical challenges faced by researchers. Sirona Dx possesses extensive experience with diverse spatial biology technologies, allowing researchers to select and optimize the suitable platform and assay for their specific applications. On the other hand, Parhelia contributes its innovative Spatial Station, a configurable automation platform designed to standardize and streamline complex spatial biology workflows.

A Vision for the Future

Nikolay Samusik, CEO of Parhelia Biosciences, emphasized the importance of high-quality, reproducible data at scale, stating: “The next challenge for spatial biology is not simply data generation; it’s about creating a workflow that consistently produces high-quality results.” This partnership seeks to empower laboratories and biopharmaceutical organizations to implement more efficient, standardized spatial biology workflows.

The collaboration will facilitate a range of spatial biology applications—encompassing techniques like cyclic immunofluorescence and imaging mass cytometry (IMC). By automating sample preparation, assay execution, and imaging processes, participating organizations can minimize operational variability while significantly cutting the costs associated with large-scale spatial biology endeavors.

Sirona Dx stands out as a technology-agnostic partner in spatial biology, enabling the use of various leading spatial platforms and modalities. This partnership will further enable organizations to transform these complex workflows into standardized and automated processes suitable for both research and clinical environments.

Nasry Yassa, CEO of Sirona Dx, noted the increasing demand from researchers and pharmaceutical organizations for workflows that can uphold scientific rigor while scaling operations. He remarked, “Together with Parhelia, we are developing an integrated approach that ensures clients can maximize data quality and simplify implementation across diverse spatial biology technologies.”

Paving the Way for Automation in Spatial Biology

Automation is poised to play an increasingly vital role in making spatial biology a routine aspect of translational research and clinical trials. By merging scientific expertise with scalable workflow infrastructure, Parhelia and Sirona Dx aim to establish a new standard for spatial biology execution. This new paradigm promises greater reproducibility, enhanced throughput, and wider access to next-generation tissue analytics.

About Parhelia Biosciences

Parhelia Biosciences specializes in the development of advanced laboratory automation platforms. The company’s Spatial Station platform focuses on enabling scalable and reproducible biological workflows, integrating sample processing, assay automation, imaging, and orchestration to expedite spatial biology programs.

For more information about Parhelia, visit www.parheliabio.com.

About Sirona Dx

Sirona Dx offers premier services in spatial biology and translational research, equipped with expertise spanning multiple technologies and disease applications. This helps biopharmaceutical and research organizations derive actionable insights from complex tissue samples, advancing biomarker-driven programs under GCLP and CLIA accreditations.

For further details about Sirona Dx, visit www.sironadx.com.